Background: We aimed to systematically compare arterial/venous thrombosis, fetal loss and stillbirth in pregnant women with systemic lupus erythematosus (SLE), primary anti-phospholipid syndrome (PAPS) and secondary anti-phospholipid syndrome (SAPS).
Methods: Online databases were carefully searched for relevant publications comparing SLE with PAPS and/or SAPS in pregnancy. Studies were included if: they compared SLE with APS [SLE versus PAPS or SLE versus SAPS or SLE versus PAPS and SAPS respectively] in pregnant women; and they reported specific adverse outcomes as their clinical endpoints including arterial/venous thrombosis, fetal loss and stillbirth. Risk ratios (RR) with 95% confidence intervals (CIs) were used as statistical parameters and the analysis was carried out by the RevMan 5.3 software.
Results: A total number of 941 pregnant women were included: 556 were candidates of SLE; 200 were candidates of PAPS; and 185 were candidates of SAPS. APS was associated with a significantly higher risk of fetal loss (RR: 4.49, 95% CI: 2.09-9.64; P = 0.0001). In addition, stillbirth and arterial/venous thrombosis were also significantly increased with APS (RR: 6.65, 95% CI: 2.14-20.60; P = 0.001) and (RR: 3.95, 95% CI: 1.28-12.16; P = 0.02) respectively. When patients with PAPS were compared with patients who suffered from SLE alone, fetal loss and arterial/venous thrombosis were still significantly higher with the former. When SAPS were compared with SLE (without anti-phospholipid antibodies), arterial/venous thrombosis, stillbirth and fetal loss were still significantly higher with SAPS. However, no significant difference was observed in arterial/venous thrombosis and fetal loss between PAPS and SAPS.
Conclusions: PAPS and SAPS were associated with significantly higher arterial/venous thrombosis, fetal loss and stillbirth in comparison to SLE. However, no significant difference was observed when PAPS was compared to SAPS.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992885 | PMC |
| http://dx.doi.org/10.1186/s12884-018-1850-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Isorhynchophylline inhibits platelet activation and thrombus formation.
J Cardiovasc Pharmacol
December 2024
Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China.
Article Synopsis
- Isorhynchophylline, a Chinese herbal medicine, shows anti-inflammatory and neuroprotective effects, but its impact on platelet function was previously unknown.
- The study found that isorhynchophylline reduces platelet aggregation and activation in a dose-dependent manner and does not affect surface levels of key receptors.
- In vivo tests on mice indicated that isorhynchophylline impairs hemostatic function and thrombus formation, suggesting it might be useful for treating thrombotic and cardiovascular diseases.
Superior Mesenteric Artery Thrombosis in COVID-19-Positive Patients: A Rare Coincidence.
Cureus
June 2024
General Surgery, Dr. D. Y. Patil Medical College, Hospital and Research Centre, Pune, IND.
Since the start of the SARS-CoV-2 pandemic, which is otherwise known as the worldwide coronavirus disease, 2019, has had a well-established pro-thrombotic character. Patients often first exhibit respiratory symptoms, and those whose severity increases eventually develop acute hypoxic respiratory failure. The systemic hypercoagulable condition and arterial/venous thrombosis related to COVID-19 have a poor prognosis.
View Article and Find Full Text PDFRetinal arterial-venous pulse delay: a new specific marker for a carotid-cavernous fistula.
Front Ophthalmol (Lausanne)
December 2023
Department of Ophthalmology and Visual Science, University of Iowa, Iowa City, IA, United States.
Purpose: The purpose of the study was to describe ocular blood flow changes in eyes affected by a carotid-cavernous fistula (CCF) using laser speckle flowgraphy. We hypothesized that imaging blood flow velocity waveforms in the retinal arterioles and venules simultaneously would reveal specific characteristics of an arteriovenous (AV) connection.
Design: The study was an observational case series, with a retrospective case-control analysis.
Antiphospholipid Syndrome and Patent Foramen Ovale: A Case Report and Literature Review.
Cureus
June 2024
Internal Medicine, Centro Hospitalar e Universitário de São João, Porto, PRT.
Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by arterial, venous, or microvascular thrombosis, pregnancy morbidity, or non-thrombotic manifestations in patients with persistent antiphospholipid antibodies (aPL). Catastrophic APS is a rare and severe form of APS that is defined by the presence of multiple vascular occlusive events. When a patent foramen ovale (PFO) is present, paradoxical embolization can occur, simultaneously leading to arterial and venous thrombosis.
View Article and Find Full Text PDFImaging of cerebrovascular complications from blunt skull base trauma.
Emerg Radiol
August 2024
Department of Imaging Sciences, University of Rochester Medical Center, Rochester, NY, USA.
Cerebrovascular complications from blunt trauma to the skull base, though rare, can lead to potentially devastating outcomes, emphasizing the importance of timely diagnosis and management. Due to the insidious clinical presentation, subtle nature of imaging findings, and complex anatomy of the skull base, diagnosing cerebrovascular injuries and their complications poses considerable challenges. This article offers a comprehensive review of skull base anatomy and pathophysiology pertinent to recognizing cerebrovascular injuries and their complications, up-to-date screening criteria and imaging techniques for assessing these injuries, and a case-based review of the spectrum of cerebrovascular complications arising from skull base trauma.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!